Huntsman Cancer Institute (HCI) Cancer Genetics, Epigenetics, Models, and Signaling (Cancer GEMS) Training Program
亨斯迈癌症研究所 (HCI) 癌症遗传学、表观遗传学、模型和信号传导(癌症 GEMS)培训计划
基本信息
- 批准号:10627604
- 负责人:
- 金额:$ 19.69万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-07-01 至 2028-06-30
- 项目状态:未结题
- 来源:
- 关键词:
项目摘要
PROJECT SUMMARY
We propose the Huntsman Cancer Institute (HCI) Cancer Genetics, Epigenetics, Models, and Signaling
(Cancer GEMS) Training Program. HCI is a National Cancer Institute-designated Comprehensive Cancer
Center and the official Cancer Center of the State of Utah. Contributing to HCI’s mission of reducing morbidity
and mortality from cancer, GEMS provides a robust two-year predoctoral training program that leverages HCI
research strengths in cancer genetics and epigenetics, cancer modeling, and cancer cell signaling, plus
integrates trainee interactions with cancer patients, cancer clinicians, and our Disease Centers, to provide
broad multidisciplinary training in cancer biology. The program goal is to prepare young scientists who are
broadly trained in cancer biology and well-versed in multidisciplinary research approaches for impactful and
rewarding opportunities in cancer-focused post-doctoral fellowships or other cancer-related research-intensive
career paths. We have carefully selected 28 experienced HCI members to serve as training faculty, with an
additional 12 promising junior faculty as associate mentors. The GEMS program will support six predoctoral
candidates per year. Trainees will be recruited into mentor’s laboratories after entering the University of Utah
(U of U) via graduate programs in Molecular Biology, Biological Chemistry, Public Health, and Population
Health Science. The program will also recruit students from our MD-PhD program. These graduate programs
recruit an average of 69 students annually, ensuring a deep pool of potential GEMS participants. GEMS
trainees will be selected based on their academic performance, promise as cancer researchers, and
commitment to transdisciplinary cancer training. Training in the GEMS program includes courses in basic and
clinical cancer biology and cancer-focused electives. To complement these didactic courses, our trainees will
have multiple opportunities to understand cancer from a clinical and patient-centric perspective. These
opportunities include broad exposure to cancer as a disease, including interactions with patients, exposure to
different operational units within HCI, physician shadowing, and attendance at Treatment Planning
Conferences. These activities are buttressed by Research-In-Progress presentations, a career development
series, and participation at an annual GEMS trainee retreat. The GEMS program is strengthened by optional
training activities, including a Master of Science in Clinical Investigation and a certificate in Genome Sciences.
GEMS trainees will receive experimental and career development advice, the latter guided by required
Individual Development Plans, from their mentor and their thesis committee. The GEMS leadership team will
receive guidance from an External Advisory Committee comprised of leaders of successful NCI T32 programs
and a Steering Committee comprised of U of U education leaders. We will use professional evaluation tools to
ensure the effectiveness of the GEMS program, and we will track trainees following completion of the program.
项目摘要
我们建议亨斯迈癌症研究所(HCI)癌症遗传学,表观遗传学,模型和信号转导
(癌症GEMS)培训计划。HCI是国家癌症研究所指定的综合癌症
中心和犹他州官方癌症中心。为HCI降低发病率的使命做出贡献
和癌症死亡率,GEMS提供了一个强大的为期两年的博士前培训计划,利用HCI
在癌症遗传学和表观遗传学、癌症建模和癌细胞信号传导方面的研究优势,以及
将受训者与癌症患者、癌症临床医生和我们的疾病中心的互动结合起来,
广泛的癌症生物学多学科培训。该计划的目标是准备年轻的科学家谁是
在癌症生物学方面接受过广泛的培训,精通多学科研究方法,
以癌症为重点的博士后奖学金或其他癌症相关研究密集型项目的奖励机会
职业道路。我们精心挑选了28名经验丰富的HCI成员作为培训教师,
增加12名有前途的初级教师作为副导师。GEMS计划将支持六个博士前
候选人每年学员进入犹他州大学后将被招募到导师的实验室
(U of U)通过分子生物学,生物化学,公共卫生和人口的研究生课程
健康科学。该计划还将招收我们的MD-PhD课程的学生。这些研究生课程
每年平均招收69名学生,确保潜在的GEMS参与者的深度池。宝石
学员将根据他们的学术表现,作为癌症研究人员的承诺,
致力于跨学科的癌症培训。GEMS计划的培训包括基础课程和
临床癌症生物学和以癌症为重点的选修课。为了补充这些教学课程,我们的学员将
有多种机会从临床和以患者为中心的角度了解癌症。这些
机会包括广泛接触癌症作为一种疾病,包括与患者的相互作用,接触
HCI内的不同操作单元、医生跟踪和治疗计划参与
两会这些活动得到了正在进行的研究报告的支持,这是一个职业发展
系列活动,并参加全球环境监测系统培训生年度务虚会。GEMS计划通过可选的
培训活动,包括临床研究理学硕士和基因组科学证书。
GEMS学员将获得实验和职业发展建议,后者由所需的指导。
个人发展计划,从他们的导师和他们的论文委员会。全球环境监测系统领导小组将
接受外部咨询委员会的指导,该委员会由成功的NCI T32计划的领导人组成
和一个指导委员会组成的U的U教育领导人。我们将使用专业的评估工具,
确保GEMS计划的有效性,我们将在计划完成后跟踪受训人员。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Donald E Ayer其他文献
Donald E Ayer的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Donald E Ayer', 18)}}的其他基金
Huntsman Cancer Institute PathMaker Programs for Cancer Research
亨斯迈癌症研究所癌症研究 PathMaker 计划
- 批准号:
10474257 - 财政年份:2019
- 资助金额:
$ 19.69万 - 项目类别:
Huntsman Cancer Institute PathMaker Programs for Cancer Research
亨斯迈癌症研究所癌症研究 PathMaker 计划
- 批准号:
10661674 - 财政年份:2019
- 资助金额:
$ 19.69万 - 项目类别:
Huntsman Cancer Institute PathMaker Programs for Cancer Research
亨斯迈癌症研究所癌症研究 PathMaker 计划
- 批准号:
9792209 - 财政年份:2019
- 资助金额:
$ 19.69万 - 项目类别:
Huntsman Cancer Institute PathMaker Programs for Cancer Research
亨斯迈癌症研究所癌症研究 PathMaker 计划
- 批准号:
10005296 - 财政年份:2019
- 资助金额:
$ 19.69万 - 项目类别:
Transcriptional control of skeletal muscle insulin resistance
骨骼肌胰岛素抵抗的转录控制
- 批准号:
8299142 - 财政年份:2010
- 资助金额:
$ 19.69万 - 项目类别:
Transcriptional control of skeletal muscle insulin resistance
骨骼肌胰岛素抵抗的转录控制
- 批准号:
8463513 - 财政年份:2010
- 资助金额:
$ 19.69万 - 项目类别:
Transcriptional control of skeletal muscle insulin resistance
骨骼肌胰岛素抵抗的转录控制
- 批准号:
7918568 - 财政年份:2010
- 资助金额:
$ 19.69万 - 项目类别:
Transcriptional control of skeletal muscle insulin resistance
骨骼肌胰岛素抵抗的转录控制
- 批准号:
8076333 - 财政年份:2010
- 资助金额:
$ 19.69万 - 项目类别:
相似海外基金
Molecular Epidemiological and pathological studies on the association between lipoprotein(a) and malignant neoplasms
脂蛋白(a)与恶性肿瘤关系的分子流行病学及病理学研究
- 批准号:
17K08718 - 财政年份:2017
- 资助金额:
$ 19.69万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Integrated analysis and detection of new therapeutic target aimed for improvement of prognosis in the patients with pancreatic malignant neoplasms
综合分析检测改善胰腺恶性肿瘤患者预后的新治疗靶点
- 批准号:
24501337 - 财政年份:2012
- 资助金额:
$ 19.69万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
GENETIC PREDISPOSITION TO SECOND MALIGNANT NEOPLASMS FOLLOWING CHILDHOOD
儿童期后第二次恶性肿瘤的遗传倾向
- 批准号:
6116914 - 财政年份:1998
- 资助金额:
$ 19.69万 - 项目类别:
GENETIC PREDISPOSITION TO SECOND MALIGNANT NEOPLASMS FOLLOWING CHILDHOOD
儿童期后第二次恶性肿瘤的遗传倾向
- 批准号:
6219852 - 财政年份:1998
- 资助金额:
$ 19.69万 - 项目类别:
GENETIC PREDISPOSITION TO SECOND MALIGNANT NEOPLASMS FOLLOWING CHILDHOOD
儿童期后第二次恶性肿瘤的遗传倾向
- 批准号:
6278109 - 财政年份:1997
- 资助金额:
$ 19.69万 - 项目类别:
SECOND MALIGNANT NEOPLASMS FOLLOWING CANCER OF THE OVARY
卵巢癌后的第二个恶性肿瘤
- 批准号:
2305338 - 财政年份:1996
- 资助金额:
$ 19.69万 - 项目类别:
SECOND MALIGNANT NEOPLASMS FOLLOWING CANCER OF THE OVARY
卵巢癌后的第二个恶性肿瘤
- 批准号:
2305324 - 财政年份:1996
- 资助金额:
$ 19.69万 - 项目类别:
SECOND MALIGNANT NEOPLASMS FOLLOWING CANCER OF THE OVARY
卵巢癌后的第二个恶性肿瘤
- 批准号:
2451660 - 财政年份:1996
- 资助金额:
$ 19.69万 - 项目类别:
SECOND MALIGNANT NEOPLASMS FOLLOWING CANCER OF THE OVARY
卵巢癌后的第二个恶性肿瘤
- 批准号:
2451659 - 财政年份:1996
- 资助金额:
$ 19.69万 - 项目类别:
SECOND MALIGNANT NEOPLASMS FOLLOWING CANCER OF THE OVARY
卵巢癌后的第二个恶性肿瘤
- 批准号:
2305309 - 财政年份:1995
- 资助金额:
$ 19.69万 - 项目类别: